Table 4. GRADE evidence profile of COVID-19 studies.
| No. of studies | Certainty assessment | No. of patients | Effect value (95% CI) | Quality of the evidence (GRADE) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Sample | Intervention | Control | ||||
| Mortality | |||||||||||
| CS [4] | Not serious | Serious1 | Not serious | Not serious | None | 737 | 329 | 408 | RR 2.00 (0.69 to 5.75) | ⨁◯◯◯ (very low) | |
| Duration of fever (d) | |||||||||||
| CS [1] | Serious2 | Not serious | Not serious | Not serious | None | 46 | 26 | 20 | WMD −3.23 (−3.56 to −2.90) | ⨁◯◯◯ (very low) | |
| Lung inflammation absorption time (d) | |||||||||||
| CS [1] | Serious2 | Not serious | Not serious | Not serious | None | 72 | 51 | 21 | WMD −1.00 (−2.91 to 0.91) | ⨁◯◯◯ (very low) | |
| Length of hospital stay (d) | |||||||||||
| CS [1] | Serious2 | Not serious | Not serious | Not serious | None | 365 | 153 | 212 | WMD 2.43 (1.42 to 3.43) | ⨁◯◯◯ (very low) | |
1, downgrade one level: heterogeneity of data synthesis results, I2>50%; 2, downgrade one level: the risk of bias is high due to the limitations of study design. RR, risk ratio; WMD, weighted mean difference; CI, confidence interval; CS, cohort study.